Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Ando, M."" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-18 z 18
    Tytuł:
    Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer.
    Autorzy:
    Hatta T; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
    Hase T; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
    Hara T; Department of Respiratory Medicine, Anjo Kosei Hospital, Anjo, Japan.
    Kimura T; Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan.
    Kojima E; Department of Respiratory Medicine, Komaki City Hospital, Komaki, Japan.
    Abe T; Department of Respiratory Medicine, Ogaki Municipal Hospital, Ogaki, Japan.
    Horio Y; Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
    Goto Y; Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
    Ozawa N; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
    Yogo N; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
    Shibata H; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
    Shimokata T; Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
    Oguri T; Department of Education and Research Center for Community Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
    Yamamoto M; Department of Respiratory Medicine, Nagoya Ekisaikai Hospital, Nagoya, Japan.
    Yanagisawa K; Division of Molecular and Cancer Medicine, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
    Ando M; Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
    Ando Y; Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
    Kondo M; Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
    Ishii M; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
    Hasegawa Y; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.; National Hospital Organization, Nagoya Medical Center, Nagoya, Japan.
    Pokaż więcej
    Źródło:
    Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (15), pp. 15955-15969. Date of Electronic Publication: 2023 Jun 23.
    Typ publikacji:
    Observational Study; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Lung Neoplasms*/drug therapy
    Antineoplastic Agents*/therapeutic use
    Carcinoma, Non-Small-Cell Lung*/drug therapy
    Humans ; Aged ; Carboplatin ; Creatinine/therapeutic use ; Treatment Outcome ; Glomerular Filtration Rate
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes.
    Autorzy:
    Sato K; Internal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama, 641-8509, Japan.
    Akamatsu H; Internal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama, 641-8509, Japan. .
    Koh Y; Internal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama, 641-8509, Japan. .; Center for Biomedical Sciences, Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama, 641-8509, Japan. .
    Ogawa K; Department of Respiratory Medicine, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-cho, Abeno-ku, Osaka-shi, Osaka, 545-8585, Japan.
    Isa SI; Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai-shi, Osaka, 591-8555, Japan.
    Ando M; Department of Advanced Medicine, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya-shi, Aichi, 466-8560, Japan.
    Tamiya A; Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai-shi, Osaka, 591-8555, Japan.
    Kubo A; Medical Oncology, Oncology Center, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute-shi, Aichi, 480-1195, Japan.
    Kitagawa C; Medical Oncology and Respiratory Medicine, National Hospital Organization Nagoya Medical Center, 4-1-1 Sannomaru, Naka-ku, Nagoya-shi, Aichi, 460-0001, Japan.
    Kawaguchi T; Department of Respiratory Medicine, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-cho, Abeno-ku, Osaka-shi, Osaka, 545-8585, Japan.
    Yamamoto N; Internal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama, 641-8509, Japan.; Center for Biomedical Sciences, Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama, 641-8509, Japan.
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2022 Nov 08; Vol. 22 (1), pp. 1148. Date of Electronic Publication: 2022 Nov 08.
    Typ publikacji:
    Multicenter Study; Journal Article
    MeSH Terms:
    Carcinoma, Non-Small-Cell Lung*/genetics
    Carcinoma, Non-Small-Cell Lung*/surgery
    Carcinoma, Non-Small-Cell Lung*/drug therapy
    Lung Neoplasms*/drug therapy
    Humans ; Proto-Oncogene Proteins p21(ras)/genetics ; ras Proteins/genetics ; Cohort Studies ; Prospective Studies ; Proto-Oncogene Proteins/genetics ; Mutation
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer.
    Autorzy:
    Matsumoto Y; Department of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
    Kawaguchi T; Department of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
    Watanabe M; Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
    Isa SI; Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Japan.
    Ando M; Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
    Tamiya A; Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Japan.
    Kubo A; Division of Respiratory Medicine and Allergology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
    Kitagawa C; Medical Oncology and Respiratory Medicine, Nagoya Medical Center, Nagoya, Japan.
    Yoshimoto N; Respiratory Medicine, Ishikiriseiki Hospital, Higashiosaka, Japan.
    Koh Y; Internal Medicine III, Wakayama Medical University, Wakayama, Japan. .; Center for Biomedical Sciences, CIMS, Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama, 641-8509, Japan. .
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2022 Jul 15; Vol. 22 (1), pp. 775. Date of Electronic Publication: 2022 Jul 15.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Carcinoma, Non-Small-Cell Lung*/drug therapy
    Carcinoma, Non-Small-Cell Lung*/genetics
    Carcinoma, Non-Small-Cell Lung*/surgery
    Lung Neoplasms*/drug therapy
    Lung Neoplasms*/genetics
    Lung Neoplasms*/surgery
    ErbB Receptors/genetics ; ErbB Receptors/therapeutic use ; Humans ; Male ; Mutation ; Neoplasm Staging ; Prognosis ; Protein Kinase Inhibitors/therapeutic use ; Retrospective Studies
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01).
    Autorzy:
    Asami K; Asami Naika Clinic, Tokyo, Japan.
    Ando M; Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
    Nishimura T; Department of Respiratory Medicine, Kyoto Katsura Hospital, Kyoto, Japan.
    Yokoi T; Department of Thoracic Oncology, Hyogo College of Medicine, Hyogo, Japan.
    Tamura A; Department of Center for Pulmonary Diseases, Tokyo National Hospital, Tokyo, Japan.
    Minato K; Department of Respiratory Medicine, Gunma Prefectural Cancer Center, Gunma, Japan.
    Mori M; Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
    Ogushi F; Department of Respiratory Medicine, Kochi National Hospital, Kochi, Japan.
    Yamamoto A; Department of Respiratory Medicine, Takamatsu Red Cross Hospital, Kagawa, Japan.
    Yoshioka H; Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan.
    Kawahara M; Department of Respiratory Medicine, KKR Otemae Hospital, Osaka, Japan.
    Atagi S; Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
    Pokaż więcej
    Źródło:
    Thoracic cancer [Thorac Cancer] 2022 Jun; Vol. 13 (12), pp. 1827-1836. Date of Electronic Publication: 2022 May 13.
    Typ publikacji:
    Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
    Carcinoma, Non-Small-Cell Lung*/drug therapy
    Carcinoma, Non-Small-Cell Lung*/genetics
    Carcinoma, Non-Small-Cell Lung*/pathology
    Lung Neoplasms*/drug therapy
    Lung Neoplasms*/genetics
    Lung Neoplasms*/pathology
    Aged ; Disease Progression ; Docetaxel/therapeutic use ; ErbB Receptors/genetics ; Gefitinib/therapeutic use ; Humans ; Mutation ; Pemetrexed/therapeutic use
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    ALKBH4 promotes tumourigenesis with a poor prognosis in non-small-cell lung cancer.
    Autorzy:
    Jingushi K; Laboratory of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan. .
    Aoki M; Department of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima, 890-8520, Japan.
    Ueda K; Department of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima, 890-8520, Japan.
    Kogaki T; Laboratory of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
    Tanimoto M; Laboratory of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
    Monoe Y; Laboratory of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
    Ando M; Laboratory of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
    Matsumoto T; Laboratory of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
    Minami K; Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima, 890-8544, Japan.
    Ueda Y; Laboratory of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
    Kitae K; Laboratory of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
    Hase H; Laboratory of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
    Nagata T; Department of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima, 890-8520, Japan.
    Harada-Takeda A; Department of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima, 890-8520, Japan.
    Yamamoto M; Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima, 890-8544, Japan.
    Kawahara K; Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima, 890-8544, Japan.
    Tabata K; Human Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, 890-8544, Japan.
    Furukawa T; Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima, 890-8544, Japan.
    Sato M; Department of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima, 890-8520, Japan.
    Tsujikawa K; Laboratory of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.
    Pokaż więcej
    Źródło:
    Scientific reports [Sci Rep] 2021 Apr 21; Vol. 11 (1), pp. 8677. Date of Electronic Publication: 2021 Apr 21.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    AlkB Homolog 4, Lysine Demethylase/*metabolism
    Carcinogenesis/*metabolism
    Carcinoma, Non-Small-Cell Lung/*metabolism
    Lung Neoplasms/*metabolism
    Animals ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Cell Line, Tumor ; Cell Proliferation ; Disease-Free Survival ; Female ; Gene Expression Regulation, Neoplastic ; Gene Knockdown Techniques ; Humans ; Lung/metabolism ; Lung Neoplasms/diagnosis ; Mice, Inbred BALB C ; Neoplasm Transplantation ; Prognosis ; Mice
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
    Autorzy:
    Noro R; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
    Kobayashi K; Department of Respiratory medicine, Saitama Medical University International Medical Center, Saitama, Japan.
    Usuki J; Department of Pulmonary Medicine, Nippon Medical School Musashikosugi Hospital, Kawasaki, Japan.
    Yomota M; Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious disease Center Komagome Hospital, Tokyo, Japan.
    Nishitsuji M; Department of Respiratory Medicine, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
    Shimokawa T; Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
    Ando M; Department of Internal Medicine, Jizankai Medical Foundation Tsuboi Cancer Center Hospital, Fukushima, Japan.
    Hino M; Department of Pulmonary Medicine, Nippon Medical School Chiba Hokuso Hospital, Chiba, Japan.
    Hagiwara K; Division of Pulmonary Medicine, Jichi Medical University, Tochigi, Japan.
    Miyanaga A; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
    Seike M; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
    Kubota K; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
    Gemma A; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
    Pokaż więcej
    Corporate Authors:
    North East Japan Study group
    Źródło:
    Thoracic cancer [Thorac Cancer] 2020 Jul; Vol. 11 (7), pp. 1876-1884. Date of Electronic Publication: 2020 May 18.
    Typ publikacji:
    Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Adenocarcinoma of Lung/*drug therapy
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Carcinoma, Non-Small-Cell Lung/*drug therapy
    Lung Neoplasms/*drug therapy
    Neoplasm Recurrence, Local/*drug therapy
    Pleural Effusion, Malignant/*drug therapy
    Pleurodesis/*adverse effects
    Adenocarcinoma of Lung/etiology ; Adenocarcinoma of Lung/pathology ; Aged ; Bevacizumab/administration & dosage ; Carboplatin/administration & dosage ; Carcinoma, Non-Small-Cell Lung/etiology ; Carcinoma, Non-Small-Cell Lung/pathology ; Docetaxel/administration & dosage ; Erlotinib Hydrochloride/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/etiology ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/etiology ; Neoplasm Recurrence, Local/pathology ; Pemetrexed/administration & dosage ; Pleural Effusion, Malignant/complications ; Pleural Effusion, Malignant/pathology ; Prognosis ; Survival Rate
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Impact of somatic mutations on prognosis in resected non-small-cell lung cancer: The Japan Molecular Epidemiology for lung cancer study.
    Autorzy:
    Tamiya A; National Hospital Organization (NHO) Kinki-Chuo Chest Medical Center, Sakai, Japan.
    Koh Y; Wakayama Medical University, Wakayama, Japan.
    Isa SI; National Hospital Organization (NHO) Kinki-Chuo Chest Medical Center, Sakai, Japan.
    Kubo A; Aichi Medical University School of Medicine, Nagakute, Japan.
    Ando M; Nagoya University Hospital Nagoya, Nagoya, Japan.
    Saka H; NHO Nagoya Medical Center, Nagoya, Japan.
    Yoshimoto N; Isikiriseiki Hospital, Higashiosaka, Japan.
    Takeo S; NHO Kyushu Medical Center, Fukuoka, Japan.
    Adachi H; NHO Hokkaido Cancer Center, Sapporo, Japan.
    Tagawa T; NHO Nagasaki Medical Center, Omura, Japan.
    Kawashima O; NHO Shibukawa Medical Center, Shibukawa, Japan.
    Yamashita M; NHO Shikoku Cancer Center, Matuyama, Japan.
    Kataoka K; NHO Iwakuni Clinical Center, Iwakuni, Japan.
    Takenoyama M; NHO Kyushu Cancer Center, Fukuoka, Japan.
    Takeuchi Y; NHO Toneyama Medical Center, Toyonaka, Japan.
    Watanabe K; NHO Yokohama Medical Center, Yokohama, Japan.
    Matsumura A; National Hospital Organization (NHO) Kinki-Chuo Chest Medical Center, Sakai, Japan.
    Kawaguchi T; Graduate School of Medicine, Osaka City University, Osaka, Japan.
    Pokaż więcej
    Źródło:
    Cancer medicine [Cancer Med] 2020 Apr; Vol. 9 (7), pp. 2343-2351. Date of Electronic Publication: 2020 Feb 05.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Mutation*
    Biomarkers, Tumor/*genetics
    Carcinoma, Non-Small-Cell Lung/*pathology
    Lung Neoplasms/*pathology
    Molecular Epidemiology/*methods
    Pneumonectomy/*mortality
    Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/epidemiology ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/surgery ; Female ; Follow-Up Studies ; Humans ; Japan/epidemiology ; Lung Neoplasms/epidemiology ; Lung Neoplasms/genetics ; Lung Neoplasms/surgery ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Survival Rate ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Resolution of Infliximab-Refractory Nivolumab-Induced Acute Severe Enterocolitis After Cyclosporine Treatment in a Patient with Non-Small Cell Lung Cancer.
    Autorzy:
    Iyoda T; Department of Pharmacy, Jizankai Medical Foundation Tsuboi Cancer Center Hospital, Koriyama, Fukushima, Japan.
    Kurita N; Department of Innovative Research and Education for Clinicians and Trainees (DiRECT), Fukushima Medical University Hospital, Fukushima City, Fukushima, Japan.; Center for Innovative Research for Communities and Clinical Excellence (CiRC²LE), Fukushima Medical University, Fukushima City, Fukushima, Japan.
    Takada A; Department of Pharmacy, Jizankai Medical Foundation Tsuboi Cancer Center Hospital, Koriyama, Fukushima, Japan.
    Watanabe H; Department of Pharmacy, Jizankai Medical Foundation Tsuboi Cancer Center Hospital, Koriyama, Fukushima, Japan.
    Ando M; Department of Pulmonology, Jizankai Medical Foundation Tsuboi Cancer Center Hospital, Koriyama, Fukushima, Japan.
    Pokaż więcej
    Źródło:
    The American journal of case reports [Am J Case Rep] 2018 Mar 27; Vol. 19, pp. 360-364. Date of Electronic Publication: 2018 Mar 27.
    Typ publikacji:
    Case Reports; Journal Article
    MeSH Terms:
    Drug Resistance*
    Antibodies, Monoclonal/*adverse effects
    Carcinoma, Non-Small-Cell Lung/*drug therapy
    Enterocolitis/*drug therapy
    Gastrointestinal Agents/*therapeutic use
    Infliximab/*therapeutic use
    Lung Neoplasms/*drug therapy
    Acute Disease ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Enterocolitis/chemically induced ; Humans ; Lung Neoplasms/diagnosis ; Male ; Middle Aged ; Nivolumab
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer.
    Autorzy:
    Ando M; Department of Preventive Medicine/Biostatistics and Medical Decision Making, Nagoya University Graduate School of Medicine, Nagoya, Japan.
    Ando Y
    Hasegawa Y
    Shimokata K
    Minami H
    Wakai K
    Ohno Y
    Sakai S
    Pokaż więcej
    Źródło:
    British journal of cancer [Br J Cancer] 2001 Nov 30; Vol. 85 (11), pp. 1634-9.
    Typ publikacji:
    Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Nursing Diagnosis*
    Physician's Role*
    Self Disclosure*
    Carcinoma, Non-Small-Cell Lung/*pathology
    Karnofsky Performance Status/*standards
    Lung Neoplasms/*pathology
    Aged ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/psychology ; Female ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/psychology ; Male ; Middle Aged ; Multivariate Analysis ; Prognosis ; Severity of Illness Index ; Survival Analysis ; Survival Rate ; Time Factors
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Induction by carbon-ion irradiation of the expression of vascular endothelial growth factor in lung carcinoma cells.
    Autorzy:
    Ando S; International Space Radiation Laboratory, National Institute of Radiological Sciences, Chiba, Japan.
    Nojima K
    Ishihara H
    Suzuki M
    Ando M
    Majima H
    Ando K
    Kuriyama T
    Pokaż więcej
    Źródło:
    International journal of radiation biology [Int J Radiat Biol] 2000 Aug; Vol. 76 (8), pp. 1121-7.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Carcinoma, Squamous Cell/*metabolism
    Carcinoma, Squamous Cell/*radiotherapy
    Endothelial Growth Factors/*biosynthesis
    Endothelial Growth Factors/*radiation effects
    Lung Neoplasms/*metabolism
    Lung Neoplasms/*radiotherapy
    Lymphokines/*biosynthesis
    Lymphokines/*radiation effects
    Carbon ; Carcinoma, Squamous Cell/genetics ; DNA Damage/radiation effects ; Dose-Response Relationship, Radiation ; Heavy Ions ; Humans ; Lung Neoplasms/genetics ; RNA, Messenger/biosynthesis ; Tumor Cells, Cultured ; Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-18 z 18

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies